Education
About Us
Working with TipRanks
Follow Us
Integra Lifesciences (IART)
:IART
IART Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.06 - $27.13
Previous CloseN/A
Volume73.30K
Average Volume (3M)1.18M
Market Cap
$991.80M
Enterprise Value$2.70B
Total Cash (Recent Filing)$253.61M
Total Debt (Recent Filing)$2.01B
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Oct 29, 2025EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding77,910,790
10 Day Avg. Volume1,570,938
30 Day Avg. Volume1,183,645
Financial Highlights & Ratios
PEG Ratio2.28
Price to Book (P/B)1.13
Price to Sales (P/S)1.08
P/FCF Ratio69.96
Enterprise Value/Market Cap2.72
Enterprise Value/Revenue1.67
Enterprise Value/Gross Profit3.17
Enterprise Value/Ebitda-7.31
Forecast
1Y Price Target
$19.00Price Target Upside49.25% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Leadership And ManagementThere is potential for a multi-year turnaround under new leadership if regulatory issues are managed effectively.
Proactive MeasuresManagement has implemented a Compliance Master Plan and partnered with third-party consulting firms to address quality issues, showing proactive steps towards improvement.
Revenue Growth PotentialManagement noted an expected increase in revenue driven by remediation efforts and higher production, which could improve financial performance in the future.
Bears Say
Earnings GuidanceThe guidance for organic revenue growth was decreased, and the explanation for this adjustment was confusing and not fully understood.
Margin PressureManagement sees gross margin down approximately 220 basis points due to tariffs and ongoing investments.
Operational ChallengesThe company is facing ongoing issues with shipholds and capacity, which are affecting its overall performance.
Integra Lifesciences News
IART FAQ
What was Integra Lifesciences’s price range in the past 12 months?
Integra Lifesciences lowest stock price was $11.06 and its highest was $27.13 in the past 12 months.
What is Integra Lifesciences’s market cap?
Integra Lifesciences’s market cap is $991.80M.
When is Integra Lifesciences’s upcoming earnings report date?
Integra Lifesciences’s upcoming earnings report date is Oct 29, 2025 which is in 82 days.
How were Integra Lifesciences’s earnings last quarter?
Integra Lifesciences released its earnings results on Jul 31, 2025. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.436 by $0.014.
Is Integra Lifesciences overvalued?
According to Wall Street analysts Integra Lifesciences’s price is currently Undervalued.
Does Integra Lifesciences pay dividends?
Integra Lifesciences does not currently pay dividends.
What is Integra Lifesciences’s EPS estimate?
Integra Lifesciences’s EPS estimate is 0.44.
How many shares outstanding does Integra Lifesciences have?
Integra Lifesciences has 77,910,790 shares outstanding.
What happened to Integra Lifesciences’s price movement after its last earnings report?
Integra Lifesciences reported an EPS of $0.45 in its last earnings report, beating expectations of $0.436. Following the earnings report the stock price went up 6.225%.
Which hedge fund is a major shareholder of Integra Lifesciences?
Currently, no hedge funds are holding shares in IART
Integra Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.00 (49.25% Upside)
$19.00 (49.25% Upside)
Blogger Sentiment
Bullish
IART Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 649.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.69%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
-9.98%
Trailing 12-Months
Company Description
Integra Lifesciences
Integra Lifesciences (IART) is a global medical technology company specializing in the development, manufacture, and marketing of innovative surgical implants and medical devices. The company primarily operates in the neurosurgery, orthopedic, and reconstructive surgery sectors, offering a wide range of products such as regenerative tissue technologies, neurosurgical and critical care solutions, and orthopedic extremity implants. Its products are designed to address the needs of healthcare professionals and improve patient outcomes across various clinical environments.
IART Company Deck
IART Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with notable achievements in the Compliance Master Plan and production improvements in Integra Skin. However, these were counterbalanced by significant challenges such as a substantial goodwill impairment charge, decline in adjusted EPS, and pressures on gross margin. While progress in risk management and operational readiness is encouraging, financial metrics and external pressures pose concerns.View all IART earnings summariesIART Stock 12 Month Forecast
Average Price Target
$19.00
▲(49.25% Upside)
Technical Analysis
Ownership Overview
3.35% Insiders
33.69% Mutual Funds
1.67% Other Institutional Investors
33.53% Public Companies and
Individual Investors